Results 31 to 40 of about 504,655 (311)

Future of Antiretroviral Drugs and Evolution of HIV-1 Drug Resistance

Viruses, 2023
Highly active antiretroviral (ARV) therapy has been used for many years, but the use in low- and middle-income countries of antiretroviral drugs with low genetic barrier to resistance, combined with limited availability of viral load testing, has led to ...
Charlotte Charpentier, Quentin Le Hingrat, Valentine Marie Ferré, Florence Damond, Diane Descamps   +4 more
doaj   +1 more source

The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study. [PDF]

, 2020
BACKGROUND:Understanding factors driving virological failure, including the contribution of HIV drug resistance mutations (DRM), is critical to ensuring HIV treatment remains effective.
Barnhart, Scott, Gilmore, Hailey J, Grignon, Jessica S, Hunt, Gillian, Liegler, Teri, Lippman, Sheri A, Mooney, Alyssa C, Prach, Lisa M, Puren, Adrian, Truong, Hong-Ha M   +9 more
core  

Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-Naïve chronic HBV patients [PDF]

, 2013
Background: Immunomodulators and Nucleotide analogues have been used globally for the dealing of chronic hepatitis B virus (HBV) infection. However, the development of drug resistance is a major limitation to their long-term effectiveness.
Abedi, F., Alavian, S.M., Ataei, B., Azad, T.M., Daram, M., Fazeli, Z., Ghamari, S., Goodarzi, Z., Jazayeri, S.M., Judaki, M.A., Kalantari, E., Karimzadeh, H., Keyvani, H., Khedive, A., Mahabadi, M., Mahmoodi, M., Malekzadeh, R., Mansour-Ghanaei, F., Montazeri, G., Moradi, A., Nejatizadeh, A., Norouzi, M., Pourhosseingholi, M.A., Rafatpanah, H., Ramezani, F., Saberfar, E., Saberfiroozi, M., Samimirad, K., Sanei-Moghaddam, I., Sarizadeh, G., Sayad, B., Somi, M.H., Yaran, M., Ziee, M.   +33 more
core   +1 more source

Patient-Initiated Repackaging of Antiretroviral Therapy, Viral Suppression and Drug Resistance [PDF]

AIDS and Behavior, 2017
Patient-initiated repackaging of antiretroviral therapy (ART) refers to removal of ART medications from their original manufacturer's containers, and putting them into alternative containers. This behavior may be triggered by stigma associated with HIV infection, and may impact patient outcomes.
Habib O, Ramadhani, Charles, Muiruri, Venance P, Maro, Balthazar, Nyombi, Michael, Omondi, Julian B, Mushi, Eileen S, Lirhunde, John A, Bartlett   +7 more
openaire   +2 more sources

HIV-1C proviral DNA for detection of drug resistance mutations. [PDF]

PLoS ONE, 2018
BACKGROUND:Using HIV proviral DNA as a template may be suitable for initial detection of transmitted drug resistance mutations (TDRMs) as it is easy to handle and less expensive compared to RNA.
Kahsay Huruy, Andargachew Mulu, Uwe Gerd Liebert, Melanie Maier   +3 more
doaj   +1 more source

Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. [PDF]

, 2009
BACKGROUND: Directly observed therapy has been recommended to improve adherence for patients with HIV infection who are on highly active antiretroviral therapy, but the benefit and cost-effectiveness of this approach has not been established conclusively.
Altice, Bayer, Berlin, Bussmann, Detsky, Edward J Mills, Farmer, Fleiss, Gross, Gross, Harrigan, Hedges, Hogg, Hozo, Jean B Nachega, Liechty, Lucas, Macalino, Maher, Mark E Engel, Maru, Maru, Maskew, Meade, Mills, Nachega, Nathan Ford, Osterberg, Page-Shipp, Pearson, Pearson, Pogue, Rigsby, Robert, Sackett, Sarna, Sherer, Simoni, Tam, Verma, Volmink, Wohl   +41 more
core   +3 more sources

Highlights from the 24th conference on retroviruses and opportunistic infections, 13-16 February 2017, Seattle, Washington, USA [PDF]

, 2017
From the 13th to 16th February 2017, researchers from around the world convened for the 24th annual Conference on Retroviruses and Opportunistic Infections (CROI) at the Washington State Convention Center in Seattle, Washington.
Bhagani, Sanjay, Colby, Donn J, Crowell, Trevor A, Gathogo, Esther N, Hill, Andrew, Hsu, Denise, Kinloch, Sabine, Lyall, Hermione, Malatinková, Eva, Polyak, Christina, Psomas, Christina, Trypsteen, Wim, Vandekerckhove, Linos   +12 more
core   +5 more sources

Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338)

AIDS Research and Therapy, 2007
Background The association between baseline drug resistance mutations and subsequent increase in viral failure has not been established for HIV-infected children.
McIntosh Kenneth, Yogev Ram, Mofenson Lynne M, Wiznia Andrew A, Hu Chengcheng, Petch Leslie A, Kovacs Andrea, Fiscus Susan A, Pelton Stephen I, Napravnik Sonia, Stanley Kenneth, Nachman Sharon A   +11 more
doaj   +1 more source

Modeling long-term longitudinal HIV dynamics with application to an AIDS clinical study

, 2009
A virologic marker, the number of HIV RNA copies or viral load, is currently used to evaluate antiretroviral (ARV) therapies in AIDS clinical trials. This marker can be used to assess the ARV potency of therapies, but is easily affected by drug exposures,
Huang, Yangxin, Lu, Tao
core   +1 more source

YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells [PDF]

, 2013
Background: The brain cancer stem cell (CSC) model describes a small subset of glioma cells as being responsible for tumor initiation, conferring therapy resistance and tumor recurrence.
Beier, Dagmar, Girbinger, Vroni, Holm, Per Sonne, Lage, Hermann, Mantwill, Klaus, Mittelbronn, Michel Guy André, Naumann, Ulrike, Schlegel, Jürgen, Seznec, Janina, Surowiak, Pawel   +9 more
core   +1 more source